These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
354 related articles for article (PubMed ID: 33704561)
1. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center. Rosa F; Galiandro F; Ricci R; Di Miceli D; Longo F; Quero G; Tortorelli AP; Alfieri S Langenbecks Arch Surg; 2021 Sep; 406(6):1847-1857. PubMed ID: 33704561 [TBL] [Abstract][Full Text] [Related]
2. Survival advantage of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced gastric cancer: experience from a Western tertiary referral center. Rosa F; Galiandro F; Ricci R; Di Miceli D; Longo F; Quero G; Tortorelli AP; Alfieri S Langenbecks Arch Surg; 2021 Jun; 406(4):1071-1080. PubMed ID: 33611693 [TBL] [Abstract][Full Text] [Related]
3. [Efficacy of 1 384 cases of peritoneal carcinomatosis underwent cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy]. Yu Y; Li XB; Lin YL; Ma R; Ji ZH; Zhang YB; An SL; Liu G; Yang XJ; Li Y Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):230-239. PubMed ID: 34645167 [No Abstract] [Full Text] [Related]
4. Cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) vs CRS alone for treatment of endometrial cancer with peritoneal metastases: a multi-institutional study from PSOGI and BIG RENAPE groups. Gomes David M; Bakrin N; Salleron J; Kaminsky MC; Bereder JM; Tuech JJ; Lehmann K; Mehta S; Glehen O; Marchal F BMC Surg; 2022 Jan; 22(1):1. PubMed ID: 34996419 [TBL] [Abstract][Full Text] [Related]
5. Novel prognostic score for outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer with metachronous peritoneal carcinomatosis. Chin KM; Tan GHC; Chia CS; Ong JCA; Teo MCC ANZ J Surg; 2020 Oct; 90(10):1958-1964. PubMed ID: 32159299 [TBL] [Abstract][Full Text] [Related]
6. Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study. Durán-Martínez M; Gómez-Dueñas G; Rodriguez-Ortíz L; Sanchez-Hidalgo JM; Gordón-Suárez A; Casado-Adam Á; Rufián-Peña S; Valenzuela-Molina F; Rufián-Andujar B; Vázquez-Borrego MC; Romero-Ruiz A; Briceño-Delgado J; Arjona-Sánchez Á Surg Endosc; 2024 Jan; 38(1):66-74. PubMed ID: 37903884 [TBL] [Abstract][Full Text] [Related]
7. Hyperthermic intraperitoneal chemotherapy (HIPEC) as adjuvant and therapeutic options for patients with advanced gastric cancer at high risk of recurrence or established peritoneal metastases: a single-centre experience. Allievi N; Bianco F; Pisano M; Montori G; Fugazzola P; Coccolini F; Lotti M; Mosconi S; Merelli B; Campanati L; Lucianetti A; Ansaloni L; Magnone S Updates Surg; 2023 Jan; 75(1):159-167. PubMed ID: 36371549 [TBL] [Abstract][Full Text] [Related]
8. Peritoneal cancer index (PCI) based patient selecting strategy for complete cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in gastric cancer with peritoneal metastasis: A single-center retrospective analysis of 125 patients. Ji ZH; Yu Y; Liu G; Zhang YB; An SL; Li B; Li XB; Yan GJ; Li Y Eur J Surg Oncol; 2021 Jun; 47(6):1411-1419. PubMed ID: 33293213 [TBL] [Abstract][Full Text] [Related]
9. Gastric cancer with peritoneal metastases: a single center outline and comparison of different surgical and intraperitoneal treatments. Santullo F; Ferracci F; Abatini C; Halabieh MAE; Lodoli C; D'Annibale G; Di Cesare L; D'Agostino L; Pecere S; Di Giorgio A; Strippoli A; Pacelli F Langenbecks Arch Surg; 2023 Nov; 408(1):437. PubMed ID: 37973620 [TBL] [Abstract][Full Text] [Related]
10. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Carcinomatosis: Multicenter Study of Spanish Group of Peritoneal Oncologic Surgery (GECOP). Manzanedo I; Pereira F; Rihuete Caro C; Pérez-Viejo E; Serrano Á; Gutiérrez Calvo A; Regueira FM; Casado-Adam Á; Cascales-Campos PA; Arteaga X; García-Fadrique A; Gómez Sanz R; López García A; Zozaya G; Arjona Á; Gil Martínez J Ann Surg Oncol; 2019 Aug; 26(8):2615-2621. PubMed ID: 31115852 [TBL] [Abstract][Full Text] [Related]
11. Comparative Analysis of Postoperative Complications after Cytoreductive Surgery and HIPEC in Gastric Cancer. Merboth F; Garcia S; V Renesse J; Distler M; Welsch T; Weitz J; Stange DE Oncol Res Treat; 2022; 45(1-2):45-53. PubMed ID: 34844244 [TBL] [Abstract][Full Text] [Related]
12. Hyperthermic intraperitoneal chemotherapy plus simultaneous versus staged cytoreductive surgery for gastric cancer with occult peritoneal metastasis. Wu X; Li Z; Li Z; Jia Y; Shan F; Ji X; Bu Z; Zhang L; Wu A; Ji J J Surg Oncol; 2015 Jun; 111(7):840-7. PubMed ID: 25864884 [TBL] [Abstract][Full Text] [Related]
13. Effect of the learning curve of cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) on the treatment of colorectal peritoneal metastasis. Chidambarasamy ES; Chia CS; Johnny Ong CA; Soo KC; Ching Teo MC; Ching Tan GH Asian J Surg; 2022 Jan; 45(1):339-345. PubMed ID: 34148748 [TBL] [Abstract][Full Text] [Related]
14. [Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy to treat peritoneal carcinomatosis from gastric cancer: a clinical study of 110 patients]. Ji ZH; Li XB; Liu G; Yu Y; Lin YL; Zhang YB; Li Y Zhonghua Yi Xue Za Zhi; 2018 Oct; 98(38):3079-3083. PubMed ID: 30392267 [No Abstract] [Full Text] [Related]
15. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for colorectal peritoneal metastases: analysis of short- and long-term outcomes. Rosa F; Galiandro F; Ricci R; Di Miceli D; Quero G; Fiorillo C; Cina C; Alfieri S Langenbecks Arch Surg; 2021 Dec; 406(8):2797-2805. PubMed ID: 34661754 [TBL] [Abstract][Full Text] [Related]
16. Treatment of Isolated Peritoneal Recurrences in Patients with Colorectal Peritoneal Metastases Previously Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. van Eden WJ; Elekonawo FMK; Starremans BJ; Kok NFM; Bremers AJA; de Wilt JHW; Aalbers AGJ Ann Surg Oncol; 2018 Jul; 25(7):1992-2001. PubMed ID: 29671139 [TBL] [Abstract][Full Text] [Related]
17. Prolonged hyperthermic intraperitoneal chemotherapy duration with 90 minutes cisplatin might increase overall survival in gastric cancer patients with peritoneal metastases. Steinhoff H; Acs M; Blaj S; Dank M; Herold M; Herold Z; Herzberg J; Sanchez-Velazquez P; Strate T; Szasz AM; Piso P World J Gastroenterol; 2023 May; 29(18):2850-2863. PubMed ID: 37274066 [TBL] [Abstract][Full Text] [Related]
18. The role of cytoreductive surgery and HIPEC for the treatment of primary and secondary peritoneal malignancies-experience from a tertiary care center in Germany. Reese M; Eichelmann AK; Nowacki TM; Pascher A; Sporn JC Langenbecks Arch Surg; 2024 Apr; 409(1):113. PubMed ID: 38589714 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy followed by hyperthermic intraperitoneal chemotherapy for patients with colorectal peritoneal metastasis: a retrospective study of its safety and efficacy. Zhou S; Jiang Y; Liang J; Pei W; Zhou Z World J Surg Oncol; 2021 May; 19(1):151. PubMed ID: 34001125 [TBL] [Abstract][Full Text] [Related]
20. Metastatic Colorectal Cancer Treated with Combined Liver Resection, Cytoreductive Surgery, and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Predictive Factors for Early Recurrence. Grange R; Rousset P; Williet N; Guesnon M; Milot L; Passot G; Phelip JM; Le Roy B; Glehen O; Kepenekian V Ann Surg Oncol; 2024 Apr; 31(4):2378-2390. PubMed ID: 38170409 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]